STOCK TITAN
  1. Home
  2. REDIF

Redhill Biopharm Stock Price, News & Analysis

REDIF OTC

Company Description

Redhill Biopharm (OTC: REDIF) is a publicly traded pharmaceuticals: major company in the Health Technology sector.

This page provides a comprehensive overview of REDIF stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-
Performance 1 year
$0.0
Market Cap
352.7M
Shares outstanding

Latest News

View All
—

RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results

earnings
—

RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares

offering
—

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients

clinical trial covid-19
—

RedHill Biopharma Presents New Talicia® and Movantik® Data Analyses at ACG 2021

—

RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034

—

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo

Redhill Biopharm has 10 recent news articles. Key topics include earnings, offering, clinical trial, covid-19, conferences. View all REDIF news →

SEC Filings

View All

No SEC filings available for REDIF.

Financial Highlights

View Full Financials
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

REDIF Company Profile & Sector Positioning

Redhill Biopharm (REDIF) operates in the Pharmaceuticals: Major industry within the broader Health Technology sector and is listed on the OTC.